Items where authors include "Nikapota, A."

Article

Huddart, R., Hafeez, S., Griffin, C. et al. (24 more authors) (2025) Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial. European Urology, 87 (1). pp. 60-70. ISSN 0302-2838

Huddart, R., Hafeez, S., Omar, A. et al. (25 more authors) (2023) Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. Clinical Oncology, 35 (9). pp. 586-597. ISSN 0936-6555

Clarke, N.W., Ali, A., Ingleby, F.C. et al. (47 more authors) (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30 (12). pp. 1992-2003. ISSN 0923-7534

Proceedings Paper

Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: Disease control data. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S704-S705.

Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: patient reported outcomes. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S331-S332.

Huddart, R.A., Hafeez, S., Omar, A. et al. (17 more authors) (2023) Randomised phase II trial of adaptive image guided radiotherapy in muscle invasive bladder cancer: Late toxicity and cancer outcomes. In: Journal of Clinical Oncology. 2023 ASCO Genitourinary Cancers Symposium, 16-18 Feb 2023. American Society of Clinical Oncology .